Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 12 entries
Sorted by: Best Match Show Resources per page
Circulating CD9+/GFAP+/survivin+ exosomes in malignant glioma patients following survivin vaccination.

Oncotarget

Galbo PM, Ciesielski MJ, Figel S, Maguire O, Qiu J, Wiltsie L, Minderman H, Fenstermaker RA.
PMID: 29383115
Oncotarget. 2017 Oct 10;8(70):114722-114735. doi: 10.18632/oncotarget.21773. eCollection 2017 Dec 29.

Glioma cells release exosomes in culture and into the extracellular matrix

Cite
Galbo PM, Ciesielski MJ, Figel S, et al. Circulating CD9+/GFAP+/survivin+ exosomes in malignant glioma patients following survivin vaccination. Oncotarget. 2017;8(70):114722-114735doi: 10.18632/oncotarget.21773.
Galbo, P. M., Ciesielski, M. J., Figel, S., Maguire, O., Qiu, J., Wiltsie, L., Minderman, H., & Fenstermaker, R. A. (2017). Circulating CD9+/GFAP+/survivin+ exosomes in malignant glioma patients following survivin vaccination. Oncotarget, 8(70), 114722-114735. https://doi.org/10.18632/oncotarget.21773
Galbo, Phillip M, et al. "Circulating CD9+/GFAP+/survivin+ exosomes in malignant glioma patients following survivin vaccination." Oncotarget vol. 8,70 (2017): 114722-114735. doi: https://doi.org/10.18632/oncotarget.21773
Galbo PM, Ciesielski MJ, Figel S, Maguire O, Qiu J, Wiltsie L, Minderman H, Fenstermaker RA. Circulating CD9+/GFAP+/survivin+ exosomes in malignant glioma patients following survivin vaccination. Oncotarget. 2017 Oct 10;8(70):114722-114735. doi: 10.18632/oncotarget.21773. eCollection 2017 Dec 29. PMID: 29383115; PMCID: PMC5777727.
Copy Download .nbib Format: NLM
Dose-Dependent Sorafenib-Induced Immunosuppression Is Associated with Aberrant NFAT Activation and Expression of PD-1 in T Cells.

Cancers

Iyer RV, Maguire O, Kim M, Curtin LI, Sexton S, Fisher DT, Schihl SA, Fetterly G, Menne S, Minderman H.
PMID: 31100868
Cancers (Basel). 2019 May 16;11(5). doi: 10.3390/cancers11050681.

The multikinase inhibitor sorafenib is the only standard first-line therapy for hepatocellular carcinoma (HCC). Here, we report the dose-dependent effects of sorafenib on the immune response, which is related to nuclear factor of activated T cells 1 (NFAT1) activity....

Cite
Iyer RV, Maguire O, Kim M, et al. Dose-Dependent Sorafenib-Induced Immunosuppression Is Associated with Aberrant NFAT Activation and Expression of PD-1 in T Cells. Cancers (Basel). 2019;11(5)doi: 10.3390/cancers11050681.
Iyer, R. V., Maguire, O., Kim, M., Curtin, L. I., Sexton, S., Fisher, D. T., Schihl, S. A., Fetterly, G., Menne, S., & Minderman, H. (2019). Dose-Dependent Sorafenib-Induced Immunosuppression Is Associated with Aberrant NFAT Activation and Expression of PD-1 in T Cells. Cancers, 11(5), . https://doi.org/10.3390/cancers11050681
Iyer, Renuka V, et al. "Dose-Dependent Sorafenib-Induced Immunosuppression Is Associated with Aberrant NFAT Activation and Expression of PD-1 in T Cells." Cancers vol. 11,5 (2019). doi: https://doi.org/10.3390/cancers11050681
Iyer RV, Maguire O, Kim M, Curtin LI, Sexton S, Fisher DT, Schihl SA, Fetterly G, Menne S, Minderman H. Dose-Dependent Sorafenib-Induced Immunosuppression Is Associated with Aberrant NFAT Activation and Expression of PD-1 in T Cells. Cancers (Basel). 2019 May 16;11(5). doi: 10.3390/cancers11050681. PMID: 31100868; PMCID: PMC6562672.
Copy Download .nbib Format: NLM
Pictet-Spengler condensations using 4-(2-aminoethyl)coumarins.

New journal of chemistry = Nouveau journal de chimie

Sviripa VM, Fiandalo MV, Begley KL, Wyrebek P, Kril LM, Balia AG, Parkin SR, Subramanian V, Chen X, Williams AH, Zhan CG, Liu C, Mohler JL, Watt DS.
PMID: 33795928
New J Chem. 2020 Aug 21;44(31):13415-13429. doi: 10.1039/d0nj02664f. Epub 2020 Jul 22.

Androgen-deprivation therapy (ADT) is only a palliative measure, and prostate cancer invariably recurs in a lethal, castration-resistant form (CRPC). Prostate cancer resists ADT by metabolizing weak, adrenal androgens to growth-promoting 5α-dihydrotestosterone (DHT), the preferred ligand for the androgen receptor...

Cite
Sviripa VM, Fiandalo MV, Begley KL, et al. Pictet-Spengler condensations using 4-(2-aminoethyl)coumarins. New J Chem. 2020;44(31):13415-13429doi: 10.1039/d0nj02664f.
Sviripa, V. M., Fiandalo, M. V., Begley, K. L., Wyrebek, P., Kril, L. M., Balia, A. G., Parkin, S. R., Subramanian, V., Chen, X., Williams, A. H., Zhan, C. G., Liu, C., Mohler, J. L., & Watt, D. S. (2020). Pictet-Spengler condensations using 4-(2-aminoethyl)coumarins. New journal of chemistry = Nouveau journal de chimie, 44(31), 13415-13429. https://doi.org/10.1039/d0nj02664f
Sviripa, Vitaliy M, et al. "Pictet-Spengler condensations using 4-(2-aminoethyl)coumarins." New journal of chemistry = Nouveau journal de chimie vol. 44,31 (2020): 13415-13429. doi: https://doi.org/10.1039/d0nj02664f
Sviripa VM, Fiandalo MV, Begley KL, Wyrebek P, Kril LM, Balia AG, Parkin SR, Subramanian V, Chen X, Williams AH, Zhan CG, Liu C, Mohler JL, Watt DS. Pictet-Spengler condensations using 4-(2-aminoethyl)coumarins. New J Chem. 2020 Aug 21;44(31):13415-13429. doi: 10.1039/d0nj02664f. Epub 2020 Jul 22. PMID: 33795928; PMCID: PMC8009307.
Copy Download .nbib Format: NLM
Chronic Adrenergic Stress Contributes to Metabolic Dysfunction and an Exhausted Phenotype in T Cells in the Tumor Microenvironment.

Cancer immunology research

Qiao G, Chen M, Mohammadpour H, MacDonald CR, Bucsek MJ, Hylander BL, Barbi JJ, Repasky EA.
PMID: 33762351
Cancer Immunol Res. 2021 Jun;9(6):651-664. doi: 10.1158/2326-6066.CIR-20-0445. Epub 2021 Mar 24.

Metabolic dysfunction and exhaustion in tumor-infiltrating T cells have been linked to ineffectual antitumor immunity and the failure of immune checkpoint inhibitor therapy. We report here that chronic stress plays a previously unrecognized role in regulating the state of...

Cite
Qiao G, Chen M, Mohammadpour H, et al. Chronic Adrenergic Stress Contributes to Metabolic Dysfunction and an Exhausted Phenotype in T Cells in the Tumor Microenvironment. Cancer Immunol Res. 2021;9(6):651-664doi: 10.1158/2326-6066.CIR-20-0445.
Qiao, G., Chen, M., Mohammadpour, H., MacDonald, C. R., Bucsek, M. J., Hylander, B. L., Barbi, J. J., & Repasky, E. A. (2021). Chronic Adrenergic Stress Contributes to Metabolic Dysfunction and an Exhausted Phenotype in T Cells in the Tumor Microenvironment. Cancer immunology research, 9(6), 651-664. https://doi.org/10.1158/2326-6066.CIR-20-0445
Qiao, Guanxi, et al. "Chronic Adrenergic Stress Contributes to Metabolic Dysfunction and an Exhausted Phenotype in T Cells in the Tumor Microenvironment." Cancer immunology research vol. 9,6 (2021): 651-664. doi: https://doi.org/10.1158/2326-6066.CIR-20-0445
Qiao G, Chen M, Mohammadpour H, MacDonald CR, Bucsek MJ, Hylander BL, Barbi JJ, Repasky EA. Chronic Adrenergic Stress Contributes to Metabolic Dysfunction and an Exhausted Phenotype in T Cells in the Tumor Microenvironment. Cancer Immunol Res. 2021 Jun;9(6):651-664. doi: 10.1158/2326-6066.CIR-20-0445. Epub 2021 Mar 24. PMID: 33762351; PMCID: PMC8355045.
Copy Download .nbib Format: NLM
Novel phosphatidylserine-binding molecule enhances antitumor T-cell responses by targeting immunosuppressive exosomes in human tumor microenvironments.

Journal for immunotherapy of cancer

Bhatta M, Shenoy GN, Loyall JL, Gray BD, Bapardekar M, Conway A, Minderman H, Kelleher RJ, Carreno BM, Linette G, Shultz LD, Odunsi K, Balu-Iyer SV, Pak KY, Bankert RB.
PMID: 34599030
J Immunother Cancer. 2021 Oct;9(10). doi: 10.1136/jitc-2021-003148.

BACKGROUND: The human tumor microenvironment (TME) is a complex and dynamic milieu of diverse acellular and cellular components, creating an immunosuppressive environment, which contributes to tumor progression. We have previously shown that phosphatidylserine (PS) expressed on the surface of...

Cite
Bhatta M, Shenoy GN, Loyall JL, et al. Novel phosphatidylserine-binding molecule enhances antitumor T-cell responses by targeting immunosuppressive exosomes in human tumor microenvironments. J Immunother Cancer. 2021;9(10)doi: 10.1136/jitc-2021-003148.
Bhatta, M., Shenoy, G. N., Loyall, J. L., Gray, B. D., Bapardekar, M., Conway, A., Minderman, H., Kelleher, R. J., Carreno, B. M., Linette, G., Shultz, L. D., Odunsi, K., Balu-Iyer, S. V., Pak, K. Y., & Bankert, R. B. (2021). Novel phosphatidylserine-binding molecule enhances antitumor T-cell responses by targeting immunosuppressive exosomes in human tumor microenvironments. Journal for immunotherapy of cancer, 9(10), . https://doi.org/10.1136/jitc-2021-003148
Bhatta, Maulasri, et al. "Novel phosphatidylserine-binding molecule enhances antitumor T-cell responses by targeting immunosuppressive exosomes in human tumor microenvironments." Journal for immunotherapy of cancer vol. 9,10 (2021). doi: https://doi.org/10.1136/jitc-2021-003148
Bhatta M, Shenoy GN, Loyall JL, Gray BD, Bapardekar M, Conway A, Minderman H, Kelleher RJ, Carreno BM, Linette G, Shultz LD, Odunsi K, Balu-Iyer SV, Pak KY, Bankert RB. Novel phosphatidylserine-binding molecule enhances antitumor T-cell responses by targeting immunosuppressive exosomes in human tumor microenvironments. J Immunother Cancer. 2021 Oct;9(10). doi: 10.1136/jitc-2021-003148. PMID: 34599030; PMCID: PMC8488709.
Copy Download .nbib Format: NLM
Purity and yield of melanoma exosomes are dependent on isolation method.

Journal of extracellular vesicles

Shu S, Yang Y, Allen CL, Hurley E, Tung KH, Minderman H, Wu Y, Ernstoff MS.
PMID: 31807236
J Extracell Vesicles. 2019 Nov 20;9(1):1692401. doi: 10.1080/20013078.2019.1692401. eCollection 2020.

Both exosomes and soluble factors have been implicated in the generation of an immunosuppressive tumour microenvironment. Determining the contribution of each requires stringent control of purity of the isolated analytes. The present study compares several conventional exosome isolation methods...

Cite
Shu S, Yang Y, Allen CL, et al. Purity and yield of melanoma exosomes are dependent on isolation method. J Extracell Vesicles. 2019;9(1):1692401doi: 10.1080/20013078.2019.1692401.
Shu, S., Yang, Y., Allen, C. L., Hurley, E., Tung, K. H., Minderman, H., Wu, Y., & Ernstoff, M. S. (2020). Purity and yield of melanoma exosomes are dependent on isolation method. Journal of extracellular vesicles, 9(1), 1692401. https://doi.org/10.1080/20013078.2019.1692401
Shu, Shin La, et al. "Purity and yield of melanoma exosomes are dependent on isolation method." Journal of extracellular vesicles vol. 9,1 (2020): 1692401. doi: https://doi.org/10.1080/20013078.2019.1692401
Shu S, Yang Y, Allen CL, Hurley E, Tung KH, Minderman H, Wu Y, Ernstoff MS. Purity and yield of melanoma exosomes are dependent on isolation method. J Extracell Vesicles. 2019 Nov 20;9(1):1692401. doi: 10.1080/20013078.2019.1692401. eCollection 2020. PMID: 31807236; PMCID: PMC6882439.
Copy Download .nbib Format: NLM
Transferrin receptor 1 upregulation in primary tumor and downregulation in benign kidney is associated with progression and mortality in renal cell carcinoma patients.

Oncotarget

Greene CJ, Attwood K, Sharma NJ, Gross KW, Smith GJ, Xu B, Kauffman EC.
PMID: 29291011
Oncotarget. 2017 Nov 06;8(63):107052-107075. doi: 10.18632/oncotarget.22323. eCollection 2017 Dec 05.

The central dysregulated pathway of clear cell (cc) renal cell carcinoma (RCC), the von Hippel Lindau/hypoxia inducible factor-α axis, is a key regulator of intracellular iron levels, however the role of iron uptake in human RCC tumorigenesis and progression...

Cite
Greene CJ, Attwood K, Sharma NJ, et al. Transferrin receptor 1 upregulation in primary tumor and downregulation in benign kidney is associated with progression and mortality in renal cell carcinoma patients. Oncotarget. 2017;8(63):107052-107075doi: 10.18632/oncotarget.22323.
Greene, C. J., Attwood, K., Sharma, N. J., Gross, K. W., Smith, G. J., Xu, B., & Kauffman, E. C. (2017). Transferrin receptor 1 upregulation in primary tumor and downregulation in benign kidney is associated with progression and mortality in renal cell carcinoma patients. Oncotarget, 8(63), 107052-107075. https://doi.org/10.18632/oncotarget.22323
Greene, Christopher J, et al. "Transferrin receptor 1 upregulation in primary tumor and downregulation in benign kidney is associated with progression and mortality in renal cell carcinoma patients." Oncotarget vol. 8,63 (2017): 107052-107075. doi: https://doi.org/10.18632/oncotarget.22323
Greene CJ, Attwood K, Sharma NJ, Gross KW, Smith GJ, Xu B, Kauffman EC. Transferrin receptor 1 upregulation in primary tumor and downregulation in benign kidney is associated with progression and mortality in renal cell carcinoma patients. Oncotarget. 2017 Nov 06;8(63):107052-107075. doi: 10.18632/oncotarget.22323. eCollection 2017 Dec 05. PMID: 29291011; PMCID: PMC5739796.
Copy Download .nbib Format: NLM
In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.

Journal for immunotherapy of cancer

Oba T, Makino K, Kajihara R, Yokoi T, Araki R, Abe M, Minderman H, Chang AE, Odunsi K, Ito F.
PMID: 34049930
J Immunother Cancer. 2021 May;9(5). doi: 10.1136/jitc-2021-002432.

BACKGROUND: Dendritic cells (DCs) are a promising therapeutic target in cancer immunotherapy given their ability to prime antigen-specific T cells, and initiate antitumor immune response. A major obstacle for DC-based immunotherapy is the difficulty to obtain a sufficient number...

Cite
Oba T, Makino K, Kajihara R, et al. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models. J Immunother Cancer. 2021;9(5)doi: 10.1136/jitc-2021-002432.
Oba, T., Makino, K., Kajihara, R., Yokoi, T., Araki, R., Abe, M., Minderman, H., Chang, A. E., Odunsi, K., & Ito, F. (2021). In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models. Journal for immunotherapy of cancer, 9(5), . https://doi.org/10.1136/jitc-2021-002432
Oba, Takaaki, et al. "In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models." Journal for immunotherapy of cancer vol. 9,5 (2021). doi: https://doi.org/10.1136/jitc-2021-002432
Oba T, Makino K, Kajihara R, Yokoi T, Araki R, Abe M, Minderman H, Chang AE, Odunsi K, Ito F. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models. J Immunother Cancer. 2021 May;9(5). doi: 10.1136/jitc-2021-002432. PMID: 34049930; PMCID: PMC8166607.
Copy Download .nbib Format: NLM
Induction of cell death in ovarian cancer cells by doxorubicin and oncolytic vaccinia virus is associated with CREB3L1 activation.

Molecular therapy oncolytics

Mistarz A, Graczyk M, Winkler M, Singh PK, Cortes E, Miliotto A, Liu S, Long M, Yan L, Stablewski A, O'Loughlin K, Minderman H, Odunsi K, Rokita H, McGray AJR, Zsiros E, Kozbor D.
PMID: 34632049
Mol Ther Oncolytics. 2021 Apr 29;23:38-50. doi: 10.1016/j.omto.2021.04.014. eCollection 2021 Dec 17.

We have demonstrated that oncolytic vaccinia virus synergizes with doxorubicin (DOX) in inducing immunogenic cell death in platinum-resistant ovarian cancer cells and increases survival in syngeneic and xenograft tumor models. However, the mechanisms underlying the virus- and doxorubicin-mediated cancer...

Cite
Mistarz A, Graczyk M, Winkler M, et al. Induction of cell death in ovarian cancer cells by doxorubicin and oncolytic vaccinia virus is associated with CREB3L1 activation. Mol Ther Oncolytics. 2021;23:38-50doi: 10.1016/j.omto.2021.04.014.
Mistarz, A., Graczyk, M., Winkler, M., Singh, P. K., Cortes, E., Miliotto, A., Liu, S., Long, M., Yan, L., Stablewski, A., O'Loughlin, K., Minderman, H., Odunsi, K., Rokita, H., McGray, A. J. R., Zsiros, E., & Kozbor, D. (2021). Induction of cell death in ovarian cancer cells by doxorubicin and oncolytic vaccinia virus is associated with CREB3L1 activation. Molecular therapy oncolytics, 2338-50. https://doi.org/10.1016/j.omto.2021.04.014
Mistarz, Anna, et al. "Induction of cell death in ovarian cancer cells by doxorubicin and oncolytic vaccinia virus is associated with CREB3L1 activation." Molecular therapy oncolytics vol. 23 (2021): 38-50. doi: https://doi.org/10.1016/j.omto.2021.04.014
Mistarz A, Graczyk M, Winkler M, Singh PK, Cortes E, Miliotto A, Liu S, Long M, Yan L, Stablewski A, O'Loughlin K, Minderman H, Odunsi K, Rokita H, McGray AJR, Zsiros E, Kozbor D. Induction of cell death in ovarian cancer cells by doxorubicin and oncolytic vaccinia virus is associated with CREB3L1 activation. Mol Ther Oncolytics. 2021 Apr 29;23:38-50. doi: 10.1016/j.omto.2021.04.014. eCollection 2021 Dec 17. PMID: 34632049; PMCID: PMC8479291.
Copy Download .nbib Format: NLM
Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research

Fountzilas C, Bajor DL, Mukherjee S, Saltzman J, Witkiewicz AK, Maguire O, Minderman H, Nambiar R, Rosenheck HR, Knudsen ES, Muhitch JB, Abrams SI, Wang C, Hutson AD, Attwood K, Hicks KA, Jurcevic JA, Kalinski P, Iyer R, Boland PM.
PMID: 34645646
Clin Cancer Res. 2021 Dec 15;27(24):6726-6736. doi: 10.1158/1078-0432.CCR-21-1650. Epub 2021 Oct 13.

PURPOSE: We evaluated the antitumor efficacy of cetuximab in combination with pembrolizumab in patients with PATIENTS AND METHODS: In this phase Ib/II study, cetuximab was combined with pembrolizumab in patients with RASwt mCRC with ≥ one prior line of...

Cite
Fountzilas C, Bajor DL, Mukherjee S, et al. Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer. Clin Cancer Res. 2021;27(24):6726-6736doi: 10.1158/1078-0432.CCR-21-1650.
Fountzilas, C., Bajor, D. L., Mukherjee, S., Saltzman, J., Witkiewicz, A. K., Maguire, O., Minderman, H., Nambiar, R., Rosenheck, H. R., Knudsen, E. S., Muhitch, J. B., Abrams, S. I., Wang, C., Hutson, A. D., Attwood, K., Hicks, K. A., Jurcevic, J. A., Kalinski, P., Iyer, R., & Boland, P. M. (2021). Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(24), 6726-6736. https://doi.org/10.1158/1078-0432.CCR-21-1650
Fountzilas, Christos, et al. "Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,24 (2021): 6726-6736. doi: https://doi.org/10.1158/1078-0432.CCR-21-1650
Fountzilas C, Bajor DL, Mukherjee S, Saltzman J, Witkiewicz AK, Maguire O, Minderman H, Nambiar R, Rosenheck HR, Knudsen ES, Muhitch JB, Abrams SI, Wang C, Hutson AD, Attwood K, Hicks KA, Jurcevic JA, Kalinski P, Iyer R, Boland PM. Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer. Clin Cancer Res. 2021 Dec 15;27(24):6726-6736. doi: 10.1158/1078-0432.CCR-21-1650. Epub 2021 Oct 13. PMID: 34645646.
Copy Download .nbib Format: NLM
Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research

Fountzilas C, Bajor DL, Mukherjee S, Saltzman J, Witkiewicz AK, Maguire O, Minderman H, Nambiar R, Rosenheck HR, Knudsen ES, Muhitch JB, Abrams SI, Wang C, Hutson AD, Attwood K, Hicks KA, Jurcevic JA, Kalinski P, Iyer R, Boland PM.
PMID: 34645646
Clin Cancer Res. 2021 Dec 15;27(24):6726-6736. doi: 10.1158/1078-0432.CCR-21-1650. Epub 2021 Oct 13.

PURPOSE: We evaluated the antitumor efficacy of cetuximab in combination with pembrolizumab in patients with PATIENTS AND METHODS: In this phase Ib/II study, cetuximab was combined with pembrolizumab in patients with RASwt mCRC with ≥ one prior line of...

Cite
Fountzilas C, Bajor DL, Mukherjee S, et al. Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer. Clin Cancer Res. 2021;27(24):6726-6736doi: 10.1158/1078-0432.CCR-21-1650.
Fountzilas, C., Bajor, D. L., Mukherjee, S., Saltzman, J., Witkiewicz, A. K., Maguire, O., Minderman, H., Nambiar, R., Rosenheck, H. R., Knudsen, E. S., Muhitch, J. B., Abrams, S. I., Wang, C., Hutson, A. D., Attwood, K., Hicks, K. A., Jurcevic, J. A., Kalinski, P., Iyer, R., & Boland, P. M. (2021). Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(24), 6726-6736. https://doi.org/10.1158/1078-0432.CCR-21-1650
Fountzilas, Christos, et al. "Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,24 (2021): 6726-6736. doi: https://doi.org/10.1158/1078-0432.CCR-21-1650
Fountzilas C, Bajor DL, Mukherjee S, Saltzman J, Witkiewicz AK, Maguire O, Minderman H, Nambiar R, Rosenheck HR, Knudsen ES, Muhitch JB, Abrams SI, Wang C, Hutson AD, Attwood K, Hicks KA, Jurcevic JA, Kalinski P, Iyer R, Boland PM. Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer. Clin Cancer Res. 2021 Dec 15;27(24):6726-6736. doi: 10.1158/1078-0432.CCR-21-1650. Epub 2021 Oct 13. PMID: 34645646.
Copy Download .nbib Format: NLM
Purity and yield of melanoma exosomes are dependent on isolation method.

Journal of extracellular vesicles

Shu S, Yang Y, Allen CL, Hurley E, Tung KH, Minderman H, Wu Y, Ernstoff MS.
PMID: 31807236
J Extracell Vesicles. 2019 Nov 20;9(1):1692401. doi: 10.1080/20013078.2019.1692401. eCollection 2020.

Both exosomes and soluble factors have been implicated in the generation of an immunosuppressive tumour microenvironment. Determining the contribution of each requires stringent control of purity of the isolated analytes. The present study compares several conventional exosome isolation methods...

Cite
Shu S, Yang Y, Allen CL, et al. Purity and yield of melanoma exosomes are dependent on isolation method. J Extracell Vesicles. 2019;9(1):1692401doi: 10.1080/20013078.2019.1692401.
Shu, S., Yang, Y., Allen, C. L., Hurley, E., Tung, K. H., Minderman, H., Wu, Y., & Ernstoff, M. S. (2020). Purity and yield of melanoma exosomes are dependent on isolation method. Journal of extracellular vesicles, 9(1), 1692401. https://doi.org/10.1080/20013078.2019.1692401
Shu, Shin La, et al. "Purity and yield of melanoma exosomes are dependent on isolation method." Journal of extracellular vesicles vol. 9,1 (2020): 1692401. doi: https://doi.org/10.1080/20013078.2019.1692401
Shu S, Yang Y, Allen CL, Hurley E, Tung KH, Minderman H, Wu Y, Ernstoff MS. Purity and yield of melanoma exosomes are dependent on isolation method. J Extracell Vesicles. 2019 Nov 20;9(1):1692401. doi: 10.1080/20013078.2019.1692401. eCollection 2020. PMID: 31807236; PMCID: PMC6882439.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 12 entries